Chronic Myelomonocytic Leukemia — Expanded Access Programs
Overview
Right2Hope maintains a directory of 41 expanded access programs, clinical trials, and compassionate use pathways listed for Chronic Myelomonocytic Leukemia. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with chronic myelomonocytic leukemia programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 17 programs are currently active or recruiting, with the remaining 24 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Center, National Cancer Institute (NCI), City of Hope Medical Center, Taiho Oncology, Inc., and others.
By recruiting status
Snapshot of where every Chronic Myelomonocytic Leukemia program currently sits in its lifecycle.
- Active / Recruiting17
- Inactive24
Top sponsors
Organisations running the most Chronic Myelomonocytic Leukemia programs in the directory.
- M.D. Anderson Cancer Center13 programs
- Fred Hutchinson Cancer Center4 programs
- National Cancer Institute (NCI)4 programs
- City of Hope Medical Center2 programs
- Taiho Oncology, Inc.2 programs
- Abhay Singh, MD MPH1 program
- Aptose Biosciences Inc.1 program
- Ascentage Pharma Group Inc.1 program
- Center for International Blood and Marrow Transplant Research1 program
- Douglas Tremblay1 program
Chronic Myelomonocytic Leukemia programs (41)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 211^At-BC8-B10 Before Donor Stem Cell Transplant for High-Risk Leukemia and Related Conditions — Fred Hutchinson Cancer Center
- Study on Radioactive Antibody and Donor Stem Cell Transplant for Treating Relapsed or Hard-to-Treat High-Risk Acute Leukemia or Myelodysplastic Syndrome — Fred Hutchinson Cancer Center
- Phase 2 Study of Olutasidenib for Patients with IDH1-mutated Blood Disorders — M.D. Anderson Cancer Center
- Study for Participants Continuing ASTX727 Treatment from Previous Clinical Trials — Taiho Oncology, Inc.
- Study on Abatacept with Cord Blood Transplant for Preventing Acute Graft Versus Host Disease — Leland Metheny
- Study on Axatilimab With or Without Azacitidine for Treating Advanced Blood Disorders and High-Risk Leukemia — Uma Borate
- Study on Azacitidine With or Without Lenalidomide or Vorinostat for Treating Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia — National Cancer Institute (NCI)
- Study on Clofarabine and Melphalan Before Donor Stem Cell Transplant for Patients with Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia — City of Hope Medical Center
- Study on Chemotherapy and Radiation Therapy Followed by Donor Cell Transplant for Treating Older Adults with High-Risk Acute Myeloid Leukemia or Other Severe Blood Cancers — Fred Hutchinson Cancer Center
- Study on Adding Pomalidomide to Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia with Myelodysplastic Syndrome-Related Changes — National Cancer Institute (NCI)
- Study on Low Dose Cyclophosphamide, Tacrolimus, and Ruxolitinib for Preventing Graft-versus-Host Disease in Stem Cell Transplant Patients — Hannah Choe, MD
- Study on Guadecitabine and Atezolizumab for Treating Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia — University of Southern California
- Study on Low Dose Weekly Decitabine and Venetoclax for Treating MDS and AML — Montefiore Medical Center
- Study on Ruxolitinib for Treating Chronic Myelomonocytic Leukemia (CMML): Phase 2 Expansion — H. Lee Moffitt Cancer Center and Research Institute
- Study on Using Geriatric Assessment to Plan Treatment for Older Adults with Blood Disorders — Memorial Sloan Kettering Cancer Center
- Study on Topotecan, Carboplatin, and Veliparib for Treating Advanced Blood Disorders and Leukemia — National Cancer Institute (NCI)
- Study on Vedolizumab, Cyclophosphamide, and Tacrolimus to Prevent Graft Versus Host Disease in Patients Undergoing Stem Cell Transplant — City of Hope Medical Center
- Phase 2 Study of Olutasidenib with Hypomethylating Agents for Patients with IDH1-mutated Blood Disorders — M.D. Anderson Cancer Center
- Phase II Study of Canakinumab for Patients with Low or Intermediate-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia — M.D. Anderson Cancer Center
- Study on APG-115 Alone or Combined with Azacitidine for Patients with AML, CMML, or MDS — Ascentage Pharma Group Inc.
- Study of ASTX030 (Cedazuridine and Azacitidine) for MDS, CMML, or AML — Taiho Oncology, Inc.
- A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML — Treadwell Therapeutics, Inc
- Study on the Safety and Effectiveness of Bexmarilimab Combined with Standard Treatment for Blood Cancers — Faron Pharmaceuticals Ltd
- Study on Ascorbic Acid and Chemotherapy for Treating Relapsed or Hard-to-Treat Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia — Mayo Clinic
- Study on Azacitidine and Enasidenib for Treating Patients with IDH2-Mutant Myelodysplastic Syndrome — M.D. Anderson Cancer Center
- Study on Azacitidine and Quizartinib for Treating Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations — M.D. Anderson Cancer Center
- Study on the Safety and Effects of Tuspetinib for Patients with Difficult-to-Treat Acute Myeloid Leukemia — Aptose Biosciences Inc.
- Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for Treating Blood Cancers — Fred Hutchinson Cancer Center
- Eltrombopag as a New Treatment for Low-risk MDS and CMML with TET2 Mutations — Abhay Singh, MD MPH
- Study on Enasidenib and Azacitidine for Treating Recurrent or Resistant Acute Myeloid Leukemia with IDH2 Gene Mutation — M.D. Anderson Cancer Center
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Reduced Cyclophosphamide for Graft Versus Host Disease Prevention — Center for International Blood and Marrow Transplant Research
- Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome — M.D. Anderson Cancer Center
- Study on Pacritinib and Azacitidine for Chronic Myelomonocytic Leukemia (CMML) — Douglas Tremblay
- Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant for Blood Cancers — M.D. Anderson Cancer Center
- Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
- Study on Tagraxofusp and Decitabine for Treating Chronic Myelomonocytic Leukemia — M.D. Anderson Cancer Center
- Study on Venetoclax and Azacitidine for Treating High-Risk Myelodysplastic Syndrome That Has Returned or Is Not Responding to Treatment — M.D. Anderson Cancer Center
- Study on Venetoclax and Decitabine for Treating Relapsed or Hard-to-Treat Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome — M.D. Anderson Cancer Center
- Study on Venetoclax and ASTX727 for Treating Chronic Myelomonocytic Leukemia and Other Related Blood Disorders — National Cancer Institute (NCI)
- Study on Venetoclax and ASTX727 for Untreated High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia — M.D. Anderson Cancer Center
- Study on Venetoclax to Improve Outcomes of Chemotherapy in Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome — M.D. Anderson Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Chronic Myelomonocytic Leukemia to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.